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Abstract. Oral cancer is a common cancer of the head and neck. 
Oral squamous cell carcinoma (OSCC) represents almost 90% 
of the total cases of head and neck cancer. Ubiquitin‑specific 
protease 22 (USP22) is a deubiquitinating hydrolase, and it is 
highly expressed in various types of cancer, which also typi-
cally have a poor prognosis. Aurora-B and Survivin, which 
belong to the chromosomal passenger complex, are also highly 
expressed in a number of types of cancer. In the present study, 
USP22 expression and its associations with Aurora-B and 
Survivin, and the clinicopathological features in OSCC were 
explored. USP22 is highly expressed in OSCC. Overexpression 
of USP22 is associated with lymph node metastasis and 
histological grade (P<0.01). Additionally, the expression of 
USP22 was positively associated with Aurora-B (P<0.01), 
Survivin (P<0.01), and Ki-67 (P<0.01). Furthermore, USP22 
small interfering RNA inhibited cell growth and reduced the 
expression levels of Aurora-B, Survivin and Cyclin B, together 
with the upregulation of cyclin-dependent kinase inhibitor 1A 
(p21). These data suggest that USP22, Aurora-B and Survivin 
promote the OSCC development and may represent novel 
targets for OSCC diagnosis and treatment in the future.
Introduction
Oral squamous cell carcinoma (OSCC) represents almost 90% 
of head and neck cancers (1). OSCC is the sixth most common 
type of malignant tumor; an estimated 50 million new cases 
occur annually worldwide, with data reported that the overall 
5-year survival rate of OSCC has remained <50% over the past 
decade (2). Although there have been a large number of studies 
at the genetic and transcriptional levels in squamous cell carci-
noma, the molecular mechanisms of carcinogenesis have not 
been completely elucidated. Therefore, identification of the 
target molecules that control the biological characteristics of 
OSCC would be of great clinical significance.
Deubiquitinating enzymes (DUBs) are a protease super-
family, which serve a role in the ubiquitin-proteasome system 
by cleaving ubiquitin chains from substrate proteins (3). 
Ubiquitin‑specific protease 22 (USP22) is a deubiquitinating 
hydrolase that belongs to the DUB family (4). The USP22 
gene is located on chromosome 17, and consists of 1578 
base pairs that encode a protein measuring 525 amino acids 
long (4,5). USP22 is weakly expressed in several human 
tissues, including the liver, skeletal muscle and heart, and 
it is also strongly expressed in various types of cancer, 
which typically have a poor prognosis, including salivary 
duct carcinoma, colorectal cancer, head and neck cancer, 
breast cancer, and hepatocellular carcinoma (HCC) (6-12). 
USP22 is also considered to be a cancer stem cell marker 
that serves a role in the development and progression of 
carcinomas (4,5). USP22 can function as a subunit of the 
human Spt-Ada-Gcn5-acetyltransferase complex, and is 
involved in the transcription of target genes (5). A previous 
study demonstrated that USP22 could inhibit the transcrip-
tion of the cyclin-dependent kinase inhibitor 1A (p21) 
gene by deubiquitinating the transcriptional regulator 
fructose-1,6-bisphosphatase (FBP1) (5). Furthermore, 
USP22 small interfering (si)RNA decreased the expression 
of Cyclin B and Survivin, and increased the expression of 
p21 in HCC (7). However, the precise mechanism by which 
USP22 affects these proteins remains unknown.
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Survivin is a member of the inhibitor of apoptosis protein 
family and is also part of the chromosomal passenger complex 
(CPC), together with Aurora B kinase, inner centromere 
protein (INCENP) and Borealin (13). The CPC functions as 
an important modulator of mitosis and cytokinesis, which 
are known to serve a crucial role in cancer cell proliferation, 
resulting in more aggressive, malignant types of cancer (13,14). 
Several studies have suggested that Survivin is overexpressed 
in a variety of human cancers; however, is barely detectable 
in the majority of differentiated tissues (15). Additionally, it 
has been reported that ubiquitin carboxyl-terminal hydrolase 
FAF-X, a deubiquitinating enzyme, regulates chromosome 
alignment and segregation by regulating the dynamic asso-
ciation of Aurora B and Survivin to centromeres (16). 
Furthermore, different cullin-based ubiquitin ligase 3 adaptors 
regulate Aurora B during mitosis, potentially by ubiquitinating 
different pools of Aurora B at distinct subcellular localiza-
tions (17). Ubiquitination regulates dynamic protein-protein 
interactions and chromosome segregation independently of 
protein degradation (16). Furthermore, USP22 is associated 
with Survivin expression in HCC (7). Therefore, we hypoth-
esize that the expression of Survivin and Aurora-B may be 
regulated by USP22 through deubiquitination.
In the present study, USP22 expression and its correlation 
with Aurora-B, Survivin and the clinicopathological features 
in OSCC were examined. The functional associations between 
USP22, Aurora-B and Survivin in OSCC were also investigated.
Materials and methods
Patients and tissue samples. A total of 90 patients (66 males 
and 24 females), who underwent complete surgical resection 
between January 2009 and June 2015 at the Affiliated Hospital 
of Guilin Medical University (Guilin, China) were enrolled in 
the present study. The inclusion criteria were: i) A diagnosis 
of OSCC confirmed by pathology; ii) Undergone surgery for 
the disease. All samples were obtained following approval by 
the Ethics Committee of Guilin Medical University (Guilin, 
China). The ages of the patients ranged from 26 to 80 years 
(mean, 56.5 years). Histologically, 70 cases were well or moder-
ately differentiated, 20 were poorly differentiated OSCC. 
Clinicopathological data, including sex, age, tumor size, 
lymph node metastasis and histological differentiation were 
recorded, the classification by the World Health Organization 
(WHO) were used for the degree of differentiation (18,19). 
Tumors from each patient were 10% formalin‑fixed in room 
temperature for 24 h and cut into 4-5 µm sections. All the 
subjects provided written informed consent.
Immunohistochemical staining. The tissue sections were 
incubated with a primary monoclonal anti-USP22 antibody 
(cat. no ab71732; 1:100; Abcam, Cambridge, MA, USA), 
monoclonal anti-Aurora-B antibody (cat. no AMI-1; 1:200; 
Transduction Laboratories, San Diego, CA, USA), the anti-Ki-67 
monoclonal antibody (cat. no MIB-1; 1:200, Dako; Agilent 
Technologies, Inc., Santa Clara, CA, USA), was used to examine 
antigen Ki-67 expression and the polyclonal anti-survivin 
antibody (1:1,000; Novus Biologicals, Littleton, CO, USA; 
cat. no. NB500-201). The sections were incubated with the 
primary antibodies at 4˚C overnight following antigen retrieval 
for 5 min at boiling temperature (100˚C) twice by microwave 
treatment in a citrate buffer solution (pH 6.0). Detection was 
performed using the avidin-biotin peroxidase complex method 
using a Labelled Strepavidin-biotin 2 (LSAB2) system-HRP 
(cat. no K0609; Dako; Agilent Technologies, Inc.), according 
to the manufacturer's protocol. The labeling index percentage 
of USP22, Aurora-B, survivin or Ki-67 was determined by 
examining ≥1,000 tumor cells in random 3 high‑powered fields 
(x200 magnification; light microscope; Olympus BX53F). 
The expression levels of Aurora-B and survivin were divided 
into low expression (<20% positive cells) and high expression 
(≥20% positive cells) groups. The expression levels of USP22 
and Ki-67 were divided into low expression (<50% positive 
cells) and high expression (≥50% positive cells).
Cell culture. The human OSCC cell line Ca9-22 was purchased 
from the Japanese Collection of Research Bioresources Cell 
Bank (Osaka, Japan). The cells were cultured in RPMI-1640 
(Gibco, Thermo Fisher Scientific Inc.) containing penicillin 
(10,000 µ/ml) and streptomycin (10,000 µg/ml) (cat. no P1400; 
Beijing Solarbio Science & Technology Co. Ltd., Beijing, 
China) with 10% fetal bovine serum (FBS; Samer Feishier 
Technology Co., Ltd.) and maintained at 37˚C in an atmosphere 
of 5% CO2. For the growth assay, 5x103 cells were plated onto 
24-well plates, and the cells were counted at days 0, 2, 4 and 6.
Western blot analysis. The Ca9-22 cells were lysed in ice-cold 
RIPA buffer (cat. no. R0020; Beijing Solarbio Science & 
Technology Co. Ltd.) with protease inhibitor for 30 min and 
centrifuged at 12,000 x g for 20 min at 4˚C. The protein concen-
tration was determined by the Bradford method (Sigma-Aldrich; 
Merck KGaA, Darmstadt, Germany) as the standard. Each 
protein lysate (40 µg) were separated on 10% SDS-PAGE gels 
and transferred to a polyvinyl difluoride membrane (Bio‑Rad 
Laboratories, Inc., Hercules, CA, USA). The membrane was 
blocked with 5% skim milk (Santa Cruz Biotechnology, Inc., 
Dallas, TX, USA) [PBS was diluted to obtain 5% milk seal 
solution (5 g/100 ml)] for 40 min at room temperature, and then 
incubated with the primary (4˚C overnight) and secondary anti-
bodies (secondary goat anti-rabbit (cat. no TA130015; 1:000) 
or anti-mouse antibody (cat. no TA100015; 1:000); OriGene 
Technologies, Inc., Rockville, MD, USA) for 1 h at room 
temperature. The primary antibodies were USP22 (1:1,000; 
Abcam; cat. no. ab71732), Survivin (cat. no. NB500-201; 
Novus Biologicals; 1:2,000), Aurora-B (cat. no AMI-1; 1:000; 
Transduction Laboratories), Cyclin B (cat. no. 610219), p21 
(cat. no. clone 70) (1:1,000; Transduction Laboratories) and 
β-actin (1:2,000, OriGene Technologies, Inc.; cat. no TA-09).
siRNA transfection. Ca9-22 cells were transfected with 
Lipofectamine® 3000 Transfection reagent (Thermo Fisher 
Scientific, Inc.) with 150 pmol USP22 siRNA (5'‑GCA GCU 
UCA AGG UGG ACA ATT-3') and negative control siRNA 
(5'-UUC UCC GAA CGU GUC ACG UTT-3') (Guangzhou 
Ribobio Co., Ltd., Guangzhou, China) in 1 ml OPTI-MEM. At 
48 h following transfection, the cells were used for subsequent 
experiments.
Statistical analysis. The data were analyzed were using the 
SPSS 17.0 software package (SPPS, Inc., Chicago, IL, USA). 
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Measurement data are presented as mean ± standard deviation. 
The χ2-test was used for the comparison of enumeration data. 
A paired student's t-test was used to compare the number of 
cells data between the siRNA-USP22 and the siRNA control 
groups. P<0.05 was considered to indicate a statistically 
significant difference.
Results
Expression of USP22, Aurora‑B, Survivin and Ki‑67 in 
OSCC tissues. Firstly, USP22 expression was compared with 
Aurora-B, Survivin and Ki-67 expression in 20 normal tissues 
and 90 OSCC by performing immunohistochemistry. In 
normal colonic mucosa, USP22, Aurora-B, Survivin and Ki-67 
were only distributed in the basal layers and exhibited weak 
staining. However, USP22, Aurora-B, Survivin and Ki-67 were 
strongly expressed in OSCC. Notably, the 4 proteins were more 
frequently expressed in poorly differentiated OSCC tissues, 
compared with the Well/Moderate-differentiated OSCC 
tissues (Fig. 1A, Tables I and II). USP22, Ki-67 and Aurora-B 
were primarily localized in the nuclei, while Survivin was 
localized to the cytoplasm and the nuclei (Fig. 1A). The 
number of high USP22, Survivin, Aurora-B and Ki-67 expres-
sion cases were 46/90 (51.11%), 51/90 (56.67%), 37/90 (41.11%) 
and 25/90 (27.78%), respectively. The number of low USP22, 
Survivin, Aurora-B and Ki-67 expression cases were 44/90 
(48.89%), 46/90 (43.33%), 53/90 (58.89%) and 65/90 (72.22%), 
respectively (Fig. 1B).
Association between USP22, Aurora‑B, Survivin and the 
clinicopathological features of OSCC. Next, the associations 
between the clinicopathological features of OSCCC and 
USP22, Aurora-B, Survivin expression and the clinicopatho-
logical features of OSCC were examined. High expression of 
USP22 was associated with lymph node metastasis (P<0.01) 
and histological grade (P<0.01), however, not with age, sex and 
tumor size in OSCC (Table I). The expression of Aurora-B 
and Survivin were associated with sex (P<0.05 and P<0.01, 
Figure 1. USP22 expression and its association with Survivin, Aurora-B and Ki-67 in OSCC. (A) Expression of USP22, Survivin, Aurora-B and Ki-67 was 
examined by immunohistochemistry in normal oral mucosa and OSCC tissues. In normal oral mucosa, USP22 were only distributed in the basal and parabasal 
layers and exhibited weak staining. In well-differentiated OSCC cases, USP22-positive cells were observed predominantly in the periphery of the tumor nests, 
while in poorly differentiated OSCC cases, USP22-positive cells were present throughout the tumor nests. The expression patterns of Survivin, Aurora-B and 
Ki-67 appear similar to USP22 in the same cases. (B) The quantity of high or low expression of USP22, Survivin, Aurora-B and Ki-67 in 90 OSCC cases. The 
quantity of high USP22, Survivin, Aurora-B and Ki-67 expression cases were 46/90, 51/90, 37/90 and 25/90 respectively. The quantity of low USP22, Survivin, 
Aurora‑B and Ki‑67 expression cases were 44/90, 46/90, 53/90 and 65/90 respectively. USP22, ubiquitin‑specific protease 22; Ki‑67, antigen Ki‑67; OSCC, 
oral squamous cell carcinoma.
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respectively), lymph node metastasis (P<0.001) and histo-
logical differentiation (P<0.01); however, not with tumor size 
and age in OSCC (Table II).
Association between USP22, Aurora‑B, Survivin and Ki‑67 
expression in OSCC. In order to understand the role of USP22, 
the present study examined the association between USP22, 
Aurora-B, Survivin and Ki-67 in OSCC. Among the 90 OSCC 
cases, 46 cases exhibited the high USP22 expression, and 44 
displayed a low USP22 expression in OSCC tissues (Table III). 
Of the 46 cases of high USP22 expression, the number of high 
Survivin, Aurora-B and Ki-67 expression cases were 33/46 
(71.74%), 27/46 (58.70%) and 20/46 (43.48%), respectively 
(Table III). Of the 44 cases with a low USP22 expression, the 
number of low Survivin, Aurora-B and Ki-67 expression cases 
were 26/44 (59.09%), 34/44 (77.27%) and 39/44 (88.64%), 
respectively (Table III). USP22 expression was positively asso-
ciated with Aurora-B, Survivin and Ki-67 (P<0.01, Table III). 
In addition, the clinicopathological findings were compared 
with the co-expression of USP22, Aurora-B and Survivin 
in OSCC. OSCC cases with a high expression of USP22, 
Aurora-B and Survivin exhibited increased lymph node 
metastasis (P<0.01) and poor differentiation (P=0.00006) 
when compared with OSCC cases with low expression of 
USP22, Aurora-B and Survivin (Table IV). These data indi-
cate that USP22 promotes the development of OSCC together 
with Aurora-B and Survivin. These data indicate that USP22 
promotes the development of OSCC together with Survivin 
and Aurora-B.
Suppression of cell growth by USP22 knockdown in OSCC 
cells. To understand the role of USP22 in the development 
of OSCC, USP22 was silenced by siRNA in OSCC cells. It 
was identified that USP22 siRNA decreased the expression 
of USP22 protein (Fig. 2A) and also inhibited cell growth in 
OSCC cells (Fig. 2B). Moreover, USP22 siRNA increased the 
p21 protein levels and decreased the Cyclin B protein levels 
in OSCC cells (Fig. 2A). Thus, we have found a possible 
relationship between USP22, Aurora-B and Survivin in OSCC 
tissues (Fig. 1 and Table III). Notably, USP22 siRNA reduced 
the protein levels of Aurora-B and Survivin in OSCC cells 
(Fig. 2B). These results suggest that the expression of Aurora-B 
and Survivin may be regulated by USP22.
Discussion
The putative cancer stem cell marker USP22 has been 
demonstrated to be overexpressed in a number of types of 
cancer (6-12). The present study identified that USP22 was 
highly expressed in OSCC, particularly in poorly differenti-
ated cancers, and that high USP22 expression was significantly 
associated with the malignant behaviors of OSCC, including 
lymph node metastasis and poor differentiation. Previous 
findings demonstrated that a high expression of USP22 was 
associated with a poor prognosis in various types of cancer, 
such as salivary duct carcinoma, colorectal cancer, head and 
neck cancer, breast cancer, and HCC (7-12). The results of 
the present study also demonstrated that USP22 expression 
was positively associated with the expression of the cell 
proliferation marker Ki-67. Additionally, it was observed 
that cell growth was suppressed by USP22 siRNA in OSCC 
cells. USP22 siRNA also increased the expression of p21 and 
reduced the expression of Cyclin B in OSCC cells. USP22 is 
a positive regulator of tumor growth and depletion of USP22 
leads to cell cycle arrest at the G1 phase (5). USP22, a member 
of the ubiquitin hydrolase family, promotes the occurrence 
and development of tumors by blocking ubiquitin-mediated 
protein degradation, including FBP1, p21, p53, c-Myc and 
BMI-1 (the Polycomb repressor complex 1), thereby enhancing 
the stability of certain cancer genes (4,17,20). Previous studies 
have demonstrated that USP22 deubiquitinates histones H2A 
and H2B and regulates cell growth, cell-cycle regulation and 
signal transduction (4,5,17). Furthermore, USP22 regulates 
cell proliferation by deubiquitinating the transcriptional regu-
lator, FBP1 (5). USP22 may also alter the expression level of 
multiple tumor-associated regulatory factors, such as c-Myc, 
BMI-1, p53, p21 and Cyclin D (14,20).
CPC contains Survivin, Borealin, Aurora-B and INCENP, 
and acts as a critical mitotic regulator that controls the cell 
cycle and serves a crucial role in the expansion of tumor 
cells (13,14). In the present study, the expression of USP22 
was identified to be positively associated with Aurora‑B and 
Survivin in OSCC. In addition, high USP22, Aurora-B, or 
Survivin expression is associated with a poor prognosis in 
OSCC, especially when all are highly expressed concomi-
tantly. Survivin inhibits apoptosis, regulates chromosome 
Table I. USP22 expression and its association with clinico-




Clinicopathological features Low High P-value
Tissue type   
  Normal 20 0 
  OSCC 44 46 
Age, years   
  ≥50 34 39 0.363
  <50 10 7 
Sex   
  Male 30 36 0.280
  Female 14 10 
Tumor size, mm   
  ≥15 20 18 0.544
  <15 24 28 
Histological differentiation
  Poor 3 17 <0.001
  Well/Moderate 41 29 
Lymph node metastasis   
  Negative 41 31 0.002
  Positive 3 15 
USP22, ubiquitin‑specific protease 22; OSCC, oral squamous cell 
carcinoma.
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separation and cell division (13-15), and is highly expressed in 
various types of cancer, which typically have a poor prognosis, 
including colorectal cancer, head and neck cancer, endo-
metrial carcinoma and hepatocellular carcinoma (7,21-26). 
Aurora-B regulates cytokinesis and chromosome segregation 
together with Survivin, Borealin and INCENP (7,8,23,24). 
Aurora B is highly expressed in a number of types of cancer, 
including head and neck, colon, liver and breast cancer, and 
is associated with malignancy indicators, including the histo-
logical differentiation and lymph node metastasis (23-26). 
USP22, Aurora-B and Survivin are highly expressed in 
OSCC, and serve an important role in the tumorigenesis 
of oral cancer most likely by disrupting cell cycle progres-
sion (23,26,27). USP22, Aurora-B and Survivin expression 
may be promising markers for predicting the malignant 
behaviors of OSCC. These observations are supported by 
previous data suggesting that high levels of Survivin and 
Aurora-B were associated with more malignant phenotypes 
and that they were independent prognostic indicators for 
multifarious cancers (9,22-26).
Our previous research demonstrated that USP22 can 
positively regulate the expression of Survivin in HCC (7); 
however, it is unclear whether USP22 regulates the expres-
sion of Aurora-B or Survivin in OSCC. In the present study, 
the results demonstrated that the expression of USP22 was 
positively associated with Aurora-B and Survivin in OSCC. A 
previous study reported that BMI-1 induces repressive epigen-
etic controlling of the Survivin promoter (16). USP22 also 
upregulates BMI-1 and may upregulate Survivin via BMI-1 
overexpression (20). Previous studies have indicated that 
Aurora-B is degraded by the ubiquitin/proteasome pathway 
in the final stage of cell division (28,29). Indeed, the present 
study identified that USP22 siRNA decreased Aurora‑B and 
Survivin expression in OSCC cells. These data indicate that 
Table II. Survivin and Aurora-B expression and their associations with clinicopathological features in oral squamous cell carcinoma.
 Survivin expression Aurora-B expression
 --------------------------------------- ---------------------------------------
Clinicopathological features Low High P-value Low High P-value
Tissue type    
  Normal 20 0  20 0 
  OSCC 39 51  53 37 
Age, years   
  ≥50 33 40 0.458 45 28 0.271
  <50 6 11  8 9 
Sex   
  Male 17 43 0.0011 34 32 0.018
  Female 16 8  19 5 
Tumor size, mm   
  ≥15 16 22 0.841 20 18 0.302
  <15 23 29  33 19 
Histological differentiation   
  Poor 2 18 0.0006 4 16 <0.001
  Well/Moderate 37 33  49 21 
Lymph node metastasis    
  Negative 36 35 0.0064 47 24 0.007
  Positive 3 16  6 13
OSCC, oral squamous cell carcinoma.
Table III. Association between USP22 and survivin, between 
USP22 and Aurora-B expression and between USP22 and 




expression (n=44) (n=46) Total P-value
Survivin    
  Low 26 13 39 0.003
  High 18 33 51 
Aurora-B    
  Low 34 19 53 0.001
  High 10 27 37 
Ki-67    
  Low 39 26 65 0.001
  High 5 20 25 
USP22, ubiquitin‑specific protease 22; Ki‑67, antigen Ki‑67.
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the expression of Survivin and Aurora-B may be regulated 
by USP22. However, the mechanism of USP22 regulating 
Survivin and Aurora-B is still unclear and needs further 
investigations.
In conclusion, the results of the present study suggest 
that USP22 may be involved in the progression of OSCC, in 
cooperation with Aurora-B and Survivin. USP22, Aurora-B 
and Survivin are markedly associated with the occurrence and 
development of OSCC and are novel potential targets for the 
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Figure 2. The effects of USP22 knockdown in OSCC cells. (A) USP22 siRNA were transfected into Ca9-22 cells. At 48 h following transfection, cells were 
collected and the expression of Survivin, Aurora-B, p21 and cyclin B was examined by western blot analysis. β-actin was used as a control. (B) Cell growth 
of siRNA treated Ca9-22 cells. At 48 h following USP22 siRNA treatment, 5,000 cells were plated on 24-well plates. At 24 h, the cell number was counted as 
0 day. The cell number was subsequently counted at days 2, 4, and 6. **P<0.01. USP22, ubiquitin‑specific protease 22; OSCC, oral squamous cell carcinoma; 
siRNA, small interfering RNA; p21, cyclin-dependent kinase inhibitor 1A.
Table IV. USP22 and survivin, and USP22 and Aurora-B expression and their associations with clinicopathological features in 
oral squamous cell carcinoma.
 USP22/survivin/Aurora-B expression
 ---------------------------------------------------------------------------------------------------------------------------------
Clinicopathological features All high (n=26) Other (n=38) All low (n=26) P-value
Age, years
  ≥50 21 31 21 0.995
  <50 5 7 5 
Sex 
  Male 22 30 14 0.025
  Female 4 8 12 
Tumor size, mm    
  ≥15 9 20 9 0.232
  <15 17 18 17 
Histological differentiation 
  Poor 13 7 0 <0.001
  Well/Moderate 13 31 26 
Lymph node metastasis  
  Negative 16 29 26 0.003
  Positive 10 9 0 
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